We have very recently demonstrated that IGF2BP3 controls the expression of the chemokine receptor CXCR4 through post-transcriptional regulation of its functional partner CD164 [129], thus promoting the motility of Ewing sarcoma cells toward the CXCR4-ligand CXCL12 under hypoxia conditions [129]. The gene discussed is IGF2BP3; the disease is Ewing sarcoma.